A Practical, Simple Approach to Prescribing SGLT-2 Inhibitors for Glycemic Control, Heart Failure, or Chronic Renal Disease in Patients with and without Type 2 Diabetes Mellitus

Main Article Content

Olivia Cook
Ally Prebtani

Keywords

SGLT-2 inhibitors, heart failure, diabetes mellitus, chronic kidney disease

Abstract

Abstract
The indications for SGLT-2 inhibitors have expanded beyond glycemic control in type 2 diabetes mellitus and now include chronic kidney disease and heart failure. These broadened indications mean more health care providers will be prescribing this class of medication on top of best evidence guideline directed therapy to improve cardiac and renal outcomes. This article reviews the effectiveness of SGLT-2i and outlines key considerations when prescribing to mitigate adverse events.


Résumé
Les indications des inhibiteurs du SGLT-2 se sont étendues au-delà du contrôle de la glycémie dans le dia-bète de type 2 et incluent maintenant les maladies rénales chroniques et l’insuffisance cardiaque. Ces indications élargies signifient qu’un plus grand nombre de fournisseurs de soins de santé prescriront cette classe de médicaments en plus du traitement dirigé par les meilleures données probantes pour améliorer les résultats cardiaques et rénaux. Cet article passe en revue l’efficacité du SGLT-2i et présente les principales considérations à prendre en compte lors de la prescription pour atténuer les effets indésirables.

Abstract 50 | PDF Downloads 40 XML Downloads 12 HTML Downloads 9

References

1. Lipscombe L., Butalia S, Dasgupta K, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. Can J Diabet. 2020;44(7):575–591. https://doi.org/10.1016/j.jcjd.2020.08.001
2. Coates PT, Devuyst O, Wong G, et al. KDIGO2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Internat. 2020;98(4):S1–S115. https://doi.org/10.1016/j.kint.2020.06.019
3. O’Meara E, McDonald M, Chan M, et al. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Can J Cardiol. 2020;36(2):159-169. doi:10.1016/j.cjca.2019.11.036
4. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;1–11.
5. Miyoshi H, Kameda H, Yamashita K, et al. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes. J Diabet Investig. 2019;10(6):1510–1517. https://doi.org/10.1111/jdi.13064
6. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–2306. https://doi.org/10.1056/nejmoa1811744
7. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436–1446. https://doi.org/10.1056/nejmoa2024816
8. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413–1424. https://doi.org/10.1056/nejmoa2022190
9. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. https://doi.org/10.1056/nejmoa1611925
10. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357. https://doi.org/10.1056/nejmoa1812389
11. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303
12. Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. J Am Heart Assoc 2020;9:e014908.
13. Solomon SD, de Boer RA, DeMets D, et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction. N Engl J Med. 2022;23(7):1217-1225.
14. Zinman B, Wanner C, Lachin J, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22).
15. Steiner S. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;13(1),17–18. https://doi.org/10.1056/nejmoa1504720
16. Koufakis T, Mustafa OG, Ajjan RA, et al. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking? J Clin Pharm Therapeut. 2020;45(5):883–891. https://doi.org/10.1111/jcpt.13107
17. Zhang L and Tamilia M. Euglycemic diabetic ketoacidosis associated with the use of a sodium glucose cotransporter-2 inhibitor. CMAJ: Canadian Medical Association Journal 2018;190(25): E766–E768. https://doi.org/10.1503/cmaj.171319
18. Qiu M, Ding LL, Zhang M, Zhou HR. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large, randomized trials of SGLT2 inhibitors. Diabetes Vasc Dis Res. 2021;18(2):10–2.